Favorable News Coverage Somewhat Unlikely to Impact Entellus Medical (ENTL) Share Price

Media coverage about Entellus Medical (NASDAQ:ENTL) has been trending positive recently, according to Accern Sentiment. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Entellus Medical earned a media sentiment score of 0.26 on Accern’s scale. Accern also gave news headlines about the medical technology company an impact score of 45.7457387117323 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of NASDAQ ENTL traded down $0.01 on Wednesday, reaching $24.00. 43,800 shares of the company traded hands, compared to its average volume of 178,331. Entellus Medical has a fifty-two week low of $11.47 and a fifty-two week high of $25.58. The company has a quick ratio of 1.71, a current ratio of 1.92 and a debt-to-equity ratio of 0.32.

How to Become a New Pot Stock Millionaire

Several research analysts recently weighed in on ENTL shares. Zacks Investment Research downgraded shares of Entellus Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. BidaskClub downgraded shares of Entellus Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday, February 17th. TheStreet raised shares of Entellus Medical from a “d” rating to a “c-” rating in a research note on Thursday, December 14th. William Blair downgraded shares of Entellus Medical from an “outperform” rating to a “market perform” rating in a research note on Friday, December 8th. Finally, ValuEngine raised shares of Entellus Medical from a “sell” rating to a “hold” rating in a research note on Thursday, December 7th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $20.33.

In related news, insider Robert S. White sold 3,471 shares of the stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $24.01, for a total transaction of $83,338.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Thomas P. Williamson sold 2,449 shares of the stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $24.08, for a total transaction of $58,971.92. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 7,623 shares of company stock valued at $183,200. Corporate insiders own 7.70% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by BBNS and is the property of of BBNS. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/04/05/entellus-medical-entl-receives-daily-news-sentiment-score-of-0-26/2024018.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.